Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Off-label tenecteplase use for acute ischemic stroke (AIS) has increased due to ease of administration and comparable efficacy and safety to alteplase.
Objective: This study aimed to evaluate time to thrombolysis before and after transition from alteplase to tenecteplase for treatment of AIS at 2 institutions.
Methods: This retrospective cohort study included adult patients receiving thrombolysis for AIS before and after transition from alteplase to tenecteplase at 2 academic medical centers from January 1, 2020 to January 31, 2024. The primary endpoint was door-to-needle (DTN) time, defined as minutes from hospital arrival to thrombolysis administration. Notable secondary endpoints included time from last known well (LKW) to thrombolysis, time from brain imaging to thrombolysis, hospital length of stay (LOS), and incidence of symptomatic intracranial hemorrhage (sICH).
Results: A total of 328 patients (168 tenecteplase and 160 alteplase) were included. Patients were 51.5% female with a median (interquartile range [IQR]) age of 70 [58-80] years and initial National Institutes of Health Stroke Scale (NIHSS) score of 8 [5-14]. There was no statistically significant difference in DTN time (60 vs 56 minutes), time from LKW to thrombolysis (134 vs 147.5 minutes), or time from brain imaging to thrombolysis (32 vs 31 minutes) between tenecteplase and alteplase. Hospital LOS (5.7 vs 4.9 days) and the rates of sICH (3% vs 3.8%) were similar between groups.
Conclusion And Relevance: Tenecteplase and alteplase had comparable DTN times for treatment of AIS and similar safety endpoints. Further studies are warranted to identify opportunities to streamline DTN times with tenecteplase.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/10600280241300230 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunomodulation and Thrombolytic Approaches in the Management of Deep Vein Thrombosis and Pulmonary Embolism.
Cardiol Cardiovasc Med
August 2025
Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, California 91766 USA.
Deep vein thrombosis (DVT) and pulmonary embolism (PE) are key initiating events in the development of venous thromboembolism (VTE), a condition associated with significant morbidity, mortality, and long-term complications. While traditional therapies have focused on anticoagulation and thrombolysis, current evidence describes the pivotal role of immune pathways in the pathogenesis and progression of thrombosis. This review explores the multifaceted mechanisms underlying DVT and PE, emphasizing the contribution of inflammation, leukocyte activation, and immuno-thrombosis to thrombus formation and embolization.
View Article and Find Full Text PDFA similar effect of fibrinogen on efficacy and safety of tenecteplase alteplase in acute ischemic cerebrovascular events (TRACE II) trial.
J Transl Int Med
June 2025
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Background And Objectives: Hemostasis factors affecting clot patterns, particularly fibrinogen, may influence the effectiveness of intravenous thrombolysis (IVT). We aimed to investigate the impact of differences in fibrinogen plasma levels on the efficacy and safety of tenecteplase alteplase in an acute ischemic cerebrovascular events-II (TRACE-II) trial.
Methods: In a multi-center, prospective, open-label, end-point blinded, randomized, controlled trial.
Efficacy and Safety of Tenecteplase in Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials.
Brain Behav
September 2025
National Heart and Lung Institute, Imperial College London, London, UK.
Introduction: Acute ischemic stroke (AIS) is the most common type of stroke, with increasing incidence and significant healthcare costs. Tenecteplase (TNK), a modified variant of tissue plasminogen activator (tPA), offers advantages such as a longer half-life and single-bolus administration. This meta-analysis evaluates the safety and efficacy of TNK compared to non-thrombolytic management in AIS to guide clinical decision-making.
View Article and Find Full Text PDFUnstable carotid plaque resembling carotid web: a diagnostic challenge in acute ischaemic stroke with rapid response to tenecteplase.
BMJ Case Rep
August 2025
Radiology, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
We present the case of an African American man in his mid-to-late 40s with no prior vascular risk factors who developed an acute ischaemic stroke. Imaging revealed an unstable carotid plaque with an associated floating thrombus, resembling a carotid web. The patient demonstrated near-complete neurological recovery within 30 min following intravenous tenecteplase administration.
View Article and Find Full Text PDFBradykinin-Mediated Angioedema Induced by Drugs.
J Clin Med
August 2025
Division of Internal Medicine 2, Department of Medicine and Medical Specialties, A. Cardarelli Hospital, 80131 Naples, Italy.
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are among the most widespread drugs for the prevention of cardiovascular mortality and morbidity. Nevertheless, they are known to cause bradykinin (BK)-mediated angioedema (AE), a paroxysmal, localized, self-limiting, and potentially fatal swelling of the subcutaneous and/or submucosal tissue, due to a temporary increase in vascular permeability. Unlike hereditary angioedema (HAE), which can be mediated similarly by BK, no diagnostic tools, guidelines, or drugs have yet been approved for the diagnosis and treatment of acute non-allergic drug-induced AE.
View Article and Find Full Text PDF